March 14, 2023
January 26, 2023
HTL accelerates its development strategy with the appointment of François Fournier as Chief Executive Officer (CEO).
HTL announces its incubator’s equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies.
HTL announces Montagu as new investor alongside its historical shareholders, Naxicap and Téthys Invest.
HTL launches a new, cutting-edge bioproduction unit for pharmaceutical-grade biopolymers.
BMG Pharma and HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology
Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer.
HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials.
HTL Biotechnology and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools
